1. Blottiere HM, Steplewski Z, Herlyn D, Douillard JY. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. Hum Antibodies Hybridomas. 1991;2:16. [PubMed] [Google Scholar]
2. Chezzolini C, Grau GE, Geinoz A, Schrijvers D. T lymphocyte interferon-gamma production induced byPlasmodium falciparum antigen is high in recently infected non-immune and low in immune subjects. Clin Exp Immunol. 1990;79:95. [PMC free article] [PubMed] [Google Scholar]
3. Fan Z, Tang ZY, Liu KD, Zhou D, Lu JZ, Yuan AN, Zhao HY. Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin: targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion. J Cancer Res Clin Oncol. 1992;118:371. [PubMed] [Google Scholar]
4. Klein JL, Leichner PK, Callahan KA, Kopher KA, Order SE. Effects of anti-antibodies on radiolabeled antibody therapy. Antibody Immunoconj Radiophar. 1988;1:55. [Google Scholar]
5. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel EA, Steinman L, Berger RG, Gaiser C, Young G, Bindle J, Hanham A, Reichert T. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood. 1991;77:20. [PubMed] [Google Scholar]
6. Ledermann JA, Begent RHJ, Massof C, Kelly AMB, Adam T, Bagshawe KD. A phase-1 study of repeated therapy with radiolabeled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer. 1991;47:659. [PubMed] [Google Scholar]
7. Lind P, Lechner P, Hausmann, Smola MG, Koeltringer P, Steindorfer P, Cesnik H, Passl R, Eber O. Development of human antimouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibody Immunoconj Radiophar. 1991;4:811. [Google Scholar]
8. Muto MG, Finkler NJ, Kassis AI, Lepisto EM, Knapp RC. Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125. Gynecol Oncol. 1990;38:244. [PubMed] [Google Scholar]
9. Oi VT, Herzenberg LA. Immunoglobulin producing hybrid cell lines. In: Mishell BB, Shiigi SM, editors. Selected methods in cellular immunology. San Francisco: Freeman; 1980. p. 351. [Google Scholar]
10. Oldham RK. Biologicals and biological response modifiers: fourth modality of cancer treatment. Cancer Treal Rep. 1984;68:221. [PubMed] [Google Scholar]
11. Paliard X, Maledijt W, Yssel H, Blanchard D, Chretien I, Abrams J, Vries JD, Spits H. Simultaneous production of IL-2, IL-4, and IFN-γ by activated human CD4+ and CD8+ T cell clones. J Immunol. 1988;141:849. [PubMed] [Google Scholar]
12. Raziuddin S, Elawad ME. Immunoregulatory CD4+CD45R+ suppressor/inducer T lymphocyte subsets and impaired cell-mediated immunity in patients with Down's syndrome. Clin Exp Immunol. 1990;79:67. [PMC free article] [PubMed] [Google Scholar]
13. Riva P, Marangolo M, Lazzari S, Agostini M, Sarti G, Moscatelli G, Franceschi G, Spinelli A, Vecchietti G. Locoregional immunotherapy of human ovarian cancer: Preliminary results. Int J Rad Appl Instrum [B] 1989;16:659. [PubMed] [Google Scholar]
14. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985;45:879. [PubMed] [Google Scholar]
15. Sears H, Herlyn D, Stepewski I, Koprowski H. The effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod. 1984;3:138. [PubMed] [Google Scholar]
16. Stewart JS, Sivolapenko GB, Hird V, Davis KA, Walport M, Ritter MA, Epenetos AA. Clearance of131-I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody. Cancer Res. 1990;50:563. [PubMed] [Google Scholar]
17. Tang ZY, Zhou HY, Zhao G, Chai LM, Zhou M, Lu JZ, Liu KD, Havas HF, Nauts HC. Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother. 1991;8:23. [PubMed] [Google Scholar]
18. Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, Lin ZY, Yang BH, Fan Z, Hou Z, Zhang M. Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol. 1991;47:27. [PubMed] [Google Scholar]
19. Tang ZY, Zeng ZC, Liu KD, Yu YQ, Lu JZ, Xie H. Intrahepatic arterial131-I anti-hepatocellular carcinoma (HCC) monoclonal antibody combined with hepatic artery ligation for treatment of unresectable HCC. Antibody Immunoconj Radiophar. 1993;6:167. [Google Scholar]
20. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Minrzer D, Dantis L, Duteau C, Templetton MA, Oettgen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988;6:1636. [PubMed] [Google Scholar]
21. Xie H, Yang ZH, Chen RM, Yao Z, Wang BM, Guo SY, Yan ZF. Two mouse hybridomas secreting monoclonal antibodies against human liver carcinoma and their antibody specificity. Acta Biol Exp Sinica. 1985;18:363. [PubMed] [Google Scholar]
22. Zeng ZC, Tang ZY, Xie H, Liu KD, Lu JZ, Chai XJ, Wang GF, Yao Z, Qian JM. Radioimmunotherapy for unresectable hepatocellular carcinoma using131-I-Hepama-1 mAb: Preliminary results. J Cancer Res Clin Oncol. 1993;119:257. [PubMed] [Google Scholar]
23. Zhang YJ, Tang ZY, Xie H, Yuan AN, Zhao HY, Lu JZ. Imaging and therapy of human hepatocellular carcinoma with radiolabeled monoclonal antibody. J Exp Clin Cancer Res. 1991;10:243. [Google Scholar]
24. Zimmer AM, Rosen ST, Spies SM, Goldman-Leikin R, Kazikiewicz JM, Silverstein EA, Kaplan EH. Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmaphoresis. J Nucl Med. 1988;29:174. [PubMed] [Google Scholar]
